Kodiak Sciences Inc. (KOD) Prices 5.19M Share Common Offering at $108/Sh

Pre-Open Stock Movers 11/17: (LXRX) (TSLA) (YY) Higher; (BCLI) (GDRX) (CODX) Lower (more...)

Today's Pre-Open Stock Movers:

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) 68.2% HIGHER; announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) 63.8% LOWER; announced today topline results from the Company's randomized, double-blind placebo-controlled Phase 3 trial evaluating NurOwn® (MSC-NTF cells) as a treatment for... More

After-Hours Stock Movers 11/16: (TSLA) (YY) (TMUS) Higher; (CODX) (FUV) (PLUG) Lower (more...)

Today's After-Hours Stock Movers:

Co-Diagnostics (NASDAQ: CODX) 13.9% LOWER; reported Q3 EPS of $0.53, $0.10 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $21.82 million versus the consensus estimate of $32.79 million.

Tesla (NASDAQ: TSLA) 11% HIGHER; will be added to the S&P 500 effective prior to the open of trading on Monday, December 21 to coincide... More

Kodiak Sciences Inc. (KOD) Announces $400M Proposed Offering of Common Stock

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has commenced an underwritten public offering of $400,000,000 of shares of its common stock. In connection with the proposed... More

Kodiak Sciences Inc. (KOD) Reports Complete Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration

Kodiak Sciences Inc. (NASDAQ: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that recruitment has concluded in its DAZZLE pivotal study of KSI-301, Kodiak's anti-VEGF antibody biopolymer conjugate, in patients with neovascular (wet) age-related macular degeneration. DAZZLE was planned to enroll 550 treatment-naïve patients worldwide; the target enrollment has been exceeded and recruitment into the study is now closed.

"We are... More

UPDATE: Morgan Stanley Downgrades Kodiak Sciences Inc. (KOD) to Equalweight

(Updated - November 16, 2020 5:47 AM EST)

(updating comment)

Morgan Stanley analyst Matthew Harrison downgraded Kodiak Sciences Inc. (NASDAQ: KOD) from Overweight to Equalweight with a price target of $125.00.

The analyst comments "We remain bullish on KSI-301's durability profile,... More